How does the drug venclexta work for cll?

How does Venclexta (venetoclax) work for CLL?

Venclexta (venetoclax) treats chronic lymphocytic leukemia (CLL) by targeting a protein called BCL-2. BCL-2 helps cancer cells avoid programmed cell death (apoptosis). Venetoclax binds to BCL-2 and blocks its protective effect, which triggers apoptosis in CLL cells [1].

Why does blocking BCL-2 kill CLL cells?

Many CLL cells rely on BCL-2 to survive. When BCL-2 is inhibited, pro-death signals inside the cell become more active, and the cancer cells die through apoptosis [1].

How is the treatment usually started (and why does it matter)?

Venetoclax is commonly started with a dose “ramp-up.” This approach is designed to reduce the risk of tumor lysis syndrome (TLS), a complication that can occur when many cancer cells die at once [1]. TLS risk is a major safety consideration early in treatment.

What determines whether a patient is at higher risk early on?

TLS risk can be influenced by factors like disease burden and baseline lab values (such as kidney function and uric acid), which your oncology team uses to decide whether you need extra preventive steps (for example, careful monitoring and supportive medications) during the initial ramp-up [1].

Sources

[1] https://www.drugpatentwatch.com/p/venclexta-venetoclax